


Albendazole for lymphatic filariasis (Review)

International Filariasis Review Group (David Addiss, Julia Critchley, Henry Ejere, Paul Garner, Hellen Gelband, Carrol Gamble)



**THE COCHRANE
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2005, Issue 3

<http://www.thecochranelibrary.com>



TABLE OF CONTENTS

ABSTRACT	1
BACKGROUND	2
OBJECTIVES	3
CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW	3
SEARCH STRATEGY FOR IDENTIFICATION OF STUDIES	4
METHODS OF THE REVIEW	4
DESCRIPTION OF STUDIES	5
METHODOLOGICAL QUALITY	6
RESULTS	6
DISCUSSION	9
AUTHORS' CONCLUSIONS	10
POTENTIAL CONFLICT OF INTEREST	10
ACKNOWLEDGEMENTS	10
SOURCES OF SUPPORT	11
REFERENCES	11
TABLES	14
Characteristics of included studies	14
Characteristics of excluded studies	16
Characteristics of ongoing studies	16
ADDITIONAL TABLES	18
Table 01. Assessment of methodological quality	18
Table 02. Microfilaraemia	18
Table 03. Antigenaemia prevalence	20
Table 04. Microfilarial density	21
Table 05. Antigenaemia density	22
Table 06. Specific adverse events	23
GRAPHS	25
Comparison 01. Albendazole versus placebo	25
Comparison 02. Albendazole versus ivermectin	25
Comparison 03. Albendazole plus ivermectin versus ivermectin	25
Comparison 04. Albendazole versus DEC	26
Comparison 05. Albendazole plus DEC versus DEC	26
INDEX TERMS	26
COVER SHEET	26
GRAPHS AND OTHER TABLES	27
Comparison 05. 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)	27
Comparison 05. 02 New clinical disease	28
Comparison 05. 03 Pre-existing clinical disease	28
Comparison 05. 04 Adverse events	28
Comparison 05. 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)	29
Comparison 05. 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)	29
Comparison 05. 02 New clinical disease	29
Comparison 05. 03 Pre-existing clinical disease	30
Comparison 05. 04 Adverse events	30
Comparison 05. 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)	31
Comparison 05. 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)	31
Comparison 05. 02 New clinical disease	31
Comparison 05. 03 Pre-existing clinical disease	32
Comparison 05. 04 Adverse events	32
Comparison 05. 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)	33
Comparison 05. 01 Microfilaraemia	33

Comparison 05. 02 Adverse events	34
Comparison 05. 03 Adverse events: scrotal syndrome	34
Comparison 05. 01 Microfilaraemia	34
Comparison 05. 02 Adverse events	35

Albendazole for lymphatic filariasis (Review)

International Filariasis Review Group (David Addiss, Julia Critchley, Henry Ejere, Paul Garner, Hellen Gelband, Carrol Gamble)

This record should be cited as:

International Filariasis Review Group (David Addiss, Julia Critchley, Henry Ejere, Paul Garner, Hellen Gelband, Carrol Gamble). Albendazole for lymphatic filariasis. *The Cochrane Database of Systematic Reviews* 2004, Issue 1. Art. No.: CD003753. DOI: 10.1002/14651858.CD003753.pub2.

This version first published online: 26 January 2004 in Issue 1, 2004.

Date of most recent substantive amendment: 24 October 2003

ABSTRACT

Background

Mass treatment with albendazole, co-administered with another antifilarial drug, is being promoted as part of a global programme to eliminate lymphatic filariasis.

Objectives

To assess the effects of albendazole on patients or populations with filarial infection, and on morbidity in patients with filarial infection; and to assess the frequency of adverse events for albendazole both given singly or in combination with another antifilarial drug (diethylcarbamazine or ivermectin).

Search strategy

We searched the Cochrane Infectious Disease Group's trial register (September 2003), the Cochrane Central Register of Controlled Trials (*The Cochrane Library* Issue 3, 2003), MEDLINE (September 2003), EMBASE (September 2003), LILACS (September 2003); and checked the reference lists and contacted experts, international organizations, and a pharmaceutical company.

Selection criteria

Randomized and quasi-randomized controlled trials of albendazole singly or in combination with anti-filarial drugs in people or populations with lymphatic filariasis.

Data collection and analysis

Two reviewers assessed eligibility and trial methodological quality. We calculated relative risks (RR) with 95% confidence intervals (CI) for binary outcomes, and where appropriate, combined them in a meta-analysis using the fixed effect model or random effects model.

Main results

Four small studies met the inclusion criteria (a total of 2473 children and adults, of whom 536 had detectable microfilariae). No effect of albendazole on microfilaraemia was demonstrated in two studies (placebo controlled, RR 0.97, 95% CI 0.87 to 1.09, n = 195). When compared to ivermectin, albendazole performed worse (RR 0.84, 95% CI 0.72 to 0.98, 2 studies of patients initially microfilariae positive, n = 198). When compared to diethylcarbamazine, no statistically significant difference was detected, but numbers were small (n = 56).

Two studies compared albendazole plus ivermectin to ivermectin alone on the presence of microfilaraemia. Results were mixed: one study showed the combination to be more effective (RR 0.27, 95% CI 0.11 to 0.70, n = 52), but the other did not demonstrate a statistically significant difference (RR 1.04, 95% CI 0.87 to 1.25, n = 145). A further study compared albendazole plus diethylcarbamazine to diethylcarbamazine alone and did not demonstrate a difference on microfilaraemia prevalence. No study examined the effects of the drugs on adult worms.

Authors' conclusions

There is insufficient reliable research to confirm or refute whether albendazole alone, or co-administered with diethylcarbamazine or ivermectin, has an effect on lymphatic filariasis.

BACKGROUND

Epidemiology

Lymphatic filariasis is a parasitic infection of threadlike, filarial worms, affecting about 120 million people in more than 80 countries (Michael 1996; WHO 2000). Bancroftian filariasis, caused by infection with *Wuchereria bancrofti* occurs in tropical regions of Asia, Africa, China, the Pacific islands, and in parts of the Caribbean and South America. Brugian filariasis is less common, with *Brugia malayi* occurring in parts of Asia, and *Brugia timori* in Indonesia (FGN 1996).

Filariasis is transmitted by mosquitoes from a number of genera (including *Culex*, *Anopheles*, *Mansonia*, *Ochlerotatus*, and *Aedes*) (Burkot 2002). Female mosquitoes transmit the disease. They are infected when they take blood meals from people with microfilariae, early stage larvae. The larvae develop for about 12 to 15 days in the mosquito to a mature larval stage (Scott 2000), which can establish itself after entering the skin and the lymphatic vessels following a subsequent blood meal. When the mosquito infects the human host, the larvae migrate to the lymph vessels and develop into adult worms, where male and female worms pair. They later produce microfilariae that migrate to the blood and cause microfilaraemia, that is, microfilariae in the blood. The time between being infected and adult worms producing microfilaraemia is estimated to be about 12 months (Mahoney 1971).

Microfilariae move in and out of circulating peripheral blood according to a daily cycle. In most species, microfilarial levels peak during the night between 10 pm to 4 am (Simonsen 1997) – a time when mosquito vectors are actively feeding. In Fiji, Polynesia, and the Philippines, some strains of *W. bancrofti* microfilariae peak during the day (Scott 2000).

Clinical features

Many people with filariasis may be asymptomatic most of the time. However, even people without clinical symptoms often have lymphatic changes, including lymphangiectasia (widening of the lymphatic vessels), and thickening of the spermatic cord (Addiss 2000; Dreyer 2000), which can be detected through imaging studies. Clinical symptoms and signs include hydrocoele (excess fluid inside the scrotal sac), lymphoedema (swelling and enlargement of affected areas of the body), and elephantiasis (long standing enlargement and swelling of the limbs, scrota, or breasts associated with skin thickening).

Historically, filarial infection has been diagnosed by examining a blood smear for microfilariae. But even if blood is taken at night, not all infections are detected because microfilarial levels are very low in many people. Antigen assays, which became available for field use during the 1990s, are more sensitive and can be used for blood collected during the day or night (Weil 1997) because they indicate the presence of the adult worm and do not depend on the temporal presence of microfilariae. Ultrasound imaging can demonstrate the presence of live adult worms (Dreyer 1995).

How the filarial worm causes disease is not well understood. The following have been proposed: adult worms living in and damaging lymph vessels; immunologic reactions to the presence and death of filarial worms; secondary infections of affected areas, which contribute significantly to both acute and chronic disease manifestations (Dreyer 2000). Researchers have also suggested that toxins released by *Wolbachia* (endosymbiotic bacteria found within the cells of filarial worms) cause disease (Taylor 2001). Some or all of these processes may be important.

Control

Control strategies aim to reduce microfilariae in the community to levels that prevent transmission (Ottesen 1997; Ottesen 1999). Treatment of individuals with clinical disease is generally only partially effective (at least in part because there is no drug that reliably kills the 'macrofilariae', the adult worms). Mass drug administration programmes therefore aim for a sustainable reduction in community microfilarial loads below a critical threshold, or a complete clearance of microfilariae, to have an appreciable impact on transmission. The 'Global Alliance to Eliminate Lymphatic Filariasis' recommend yearly, single-dose, two-drug regimens (either albendazole plus diethylcarbamazine (DEC); or albendazole plus ivermectin), for at least five years (corresponding to the reproductive lifespan of the adult worm) to prevent transmission. However, the critical threshold below which no further transmission will take place is unclear, and may depend on the vector species in the locality. Some mosquitoes (for example, *Aedes polynesiensis*, some culicine mosquitoes in India and the Americas) may be more efficient at lower microfilarial densities (a process known as limitation). Higher treatment coverage for longer periods, or other strategies such as vector control, may be required in areas where these vectors are responsible for a high proportion of transmission (Burkot 2002; Pichon 2002).

Ivermectin and DEC both kill microfilariae, and DEC may have some temporary sterilizing effect or actually kill adult worms, so one treatment with either drug can affect microfilarial levels for many months. Reductions of 90% from pre-treatment microfilarial levels have been seen after single dose DEC or ivermectin, even one year after treatment (Ottesen 1999). The impact on transmission can be enhanced, if currently available antifilarial drugs demonstrate a killing or sterilizing effect on adult worms, in addition to their effect on microfilariae. There are concerns that over reliance on a limited range of drugs may eventually cause resistance, although there is little direct evidence that this is currently a problem in filariasis (Barat 1997; Geerts 2001).

It has been observed that some infected people lose their microfilariae in the absence of treatment (Vanamail 1990). However, overall microfilarial prevalence rates are believed to be relatively stable over time in endemic communities in the absence of community treatment (Meyrowitsch 1995), with new, microfilaraemic infections replacing those whose microfilaraemia subsides (Vanamail 1990; Weil 1999). Nevertheless, lymphatic filariasis has been

eliminated from some areas such as the Choiseul Island (Solomon Islands) and Australia using vector control methods (Pichon 2002; Burkot 2002), and parts of China using DEC-medicated salt and other DEC regimens (Gelband 1994).

Diethylcarbamazine and ivermectin

DEC has been in use for filariasis for more than 50 years. In the early years of control the recommended regimen for DEC was 6 mg/kg daily for 12 days (WHO 1984). Later, clinical and community trials determined that single doses given at various intervals – weekly, monthly, annually, and biannually – were equally effective (Eberhard 1989; Andrade 1995; Simonsen 1995). There is reasonable evidence from ultrasound and clinical observations that DEC kills some adult worms (macrofilariae) after single doses (Figueredo-Silva 1996; Noroes 1997; Addiss 2000).

Ivermectin is used for the treatment and community control of onchocerciasis (which is caused by another filarial worm, *Onchocerca volvulus*) and more recently has been effective in community control programs for lymphatic filariasis (Cartel 1990; Coutinho 1994; Cao 1997). It can be used in many places, but is particularly important in areas where both onchocerciasis and lymphatic filariasis coexist, because DEC can cause eye damage if given to individuals with onchocerciasis. However, recent ultrasound studies suggest that adult worms are not killed by ivermectin, even at high doses over a period of six months (Dreyer 1996; Addiss 2000).

Adverse effects of antifilarial drugs can be serious (though almost never fatal) and prevent people from completing treatment. The most serious appear to be due to a host immunologic reaction to the dying worms (WHO 1984; Dreyer 1994). These effects include fever, headache, malaise, muscle pain, and blood in urine. Local effects include localized pain, tender nodules, lymphadenitis (inflammation of the lymph nodes), and lymphangitis (inflammation of lymph vessels) (Addiss 2000).

Albendazole

Albendazole has been used widely to treat intestinal parasites since the late 1980s and may have a potential role in lymphatic filariasis control (Ottesen 1999). A report from an informal consultation organized by the World Health Organization suggests that albendazole in repeated high doses has a killing or sterilizing effect on adults of *W. bancrofti* (CDS/FIL 1998; Sri Lanka (Jaya 1993)). However, the data in the report are scanty and it remains unclear whether adding albendazole to either DEC or ivermectin improves cure, prevents further transmission, or influences the occurrence of adverse events. A narrative review by Horton 2000 from the company that manufactures albendazole did not demonstrate that adding albendazole to either drug increased the frequency or severity of adverse events. The company manufacturing albendazole state that this drug does not have a role in morbidity management – it will not treat the symptoms in people already affected by filariasis (GSK 2003) – but at least one trial has considered the effectiveness of albendazole in reducing both disease progression and

incidence of new symptoms (such as hydrocoele) (Ghana (Dunyo 2000)). We therefore include this as a secondary outcome.

In this review, we aim to summarize the evidence for the effects of albendazole alone or in combination with DEC or ivermectin in both the individual treatment and transmission control of lymphatic filariasis.

OBJECTIVES

- (1) To assess the effects of albendazole on patients or populations with filarial infection.
- (2) To assess the effects of albendazole on morbidity among patients with filarial infection (incidence of new disease or progression of existing symptoms)
- (3) To assess the frequency of adverse events for albendazole both given singly or in combination with another antifilarial drug (DEC or ivermectin).

CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW

Types of studies

- Randomized controlled trials.
- Cluster randomized controlled trials.
- Quasi-randomized controlled trials (controlled clinical trials with non-randomized methods of treatment allocation such as alternate allocation).

Types of participants

- Adults or children with filarial infection defined by (1) the presence of microfilariae parasites in the blood, (2) filarial antigens in the blood, or (3) ultrasound detection of adult worms in lymphatic vessels.
- Populations normally resident in endemic communities and who are eligible for treatment regardless of microfilaraemia status (community trials).

Types of intervention

- Albendazole alone versus placebo.
- Albendazole alone versus DEC.
- Albendazole alone versus ivermectin.
- Albendazole plus DEC versus DEC (DEC dose and regimen same in both arms).
- Albendazole plus ivermectin versus ivermectin (ivermectin dose and regimen same in both arms).

Types of outcome measures

Primary

- Microfilaraemia (detectable microfilariae).
- Macrofilaria viability (live adult worms detected by ultrasound).
- Microfilarial density.
- Community microfilarial density (in mass treatment trials).
- Antigenaemia prevalence or density.

Secondary (clinical disease)

- Acute filariasis (fever combined with clinical evidence of inflammation of the lymphatic system, as defined by trial authors).
- Appearance of hydrocoele or lymphoedema.
- Reduction in size of hydrocoele or lymphoedema.

Adverse events

- Any adverse events that prevent daily activities or require hospitalization.
- Systemic adverse events (for example, fever, headache, malaise, myalgia, or haematuria).
- Local adverse events (for example, localized pain and inflammation, tender nodules, lymphadenitis, or lymphangitis).

SEARCH STRATEGY FOR IDENTIFICATION OF STUDIES

See: search strategy

We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and in progress).

We used the following search terms for all trial registers and databases: filariasis; lymphatic filariasis; elephantiasis; lymphoedema; *Wuchereria bancrofti*; *Brugia malayi*; *Brugia timori*; filaricides; diethylcarbamazine; banocide; carbamazine; hetrazan; luxuran; ivermectin; mectizan; benzimidazole; albendazole; metiazol; and valbazen.

We searched the Cochrane Infectious Diseases Group's trials register up to September 2003 (full details of the Cochrane Infectious Diseases Group's methods are published in *The Cochrane Library* in the section on Collaborative Review Groups) and the Cochrane Central Register of Controlled Trials (CENTRAL) (*The Cochrane Library* Issue 3, 2003).

We searched the following electronic databases using the search strategy defined by The Cochrane Collaboration (Clarke 2003): MEDLINE (1966 to September 2003); EMBASE (1980 to September 2003); and LILACS (www.bireme.br; 1982 to September 2003).

To help identify unpublished and ongoing trials, we held meetings with representatives of the World Health Organization

and GlaxoSmithKline (the company producing albendazole), and contacted experts including David Molyneux, Janis Lazdins, Vasanthapura Kumaraswami, and Graham White.

We checked the reference lists of existing reviews and of all identified trials for further reports.

METHODS OF THE REVIEW

Study selection

One reviewer (Henry Ejere (HE) or Julia Critchley (JC)) screened titles and abstracts identified from the search strategy. We retrieved hard copies of the published or unpublished trial reports potentially relevant to the review for further assessment. We used a predesigned eligibility form to select studies and included trials that met the inclusion criteria (HE or JC and Paul Garner (PG)). We resolved disagreements through discussion.

Assessment of the methodological quality

Two reviewers (HE or JC and PG) independently assessed trials according to predefined quality criteria in relation to generation of allocation sequence; concealment of allocation; blinding of participants, investigators, and outcome assessors; and completeness of follow up (less than 10% loss to follow up defined as adequate). We assessed each criterion (except blinding) as adequate, inadequate, or unclear according to Juni 2001. We assessed blinding as double blind (trial uses a placebo or a double dummy technique such that neither the participant or care provider/assessor knows which treatment is given), single blind (participant or care provider/assessor is aware of the treatment given), or open (all parties are aware of treatment).

Data collection

One reviewer extracted data (HE or JC), and a second reviewer checked them (PG). Where studies reported the same outcomes in different ways, we attempted to contact the trial authors for further information, which might allow us to transform and therefore pool data. HE entered data into Review Manager 4.1. We extracted data relating to trial and participant characteristics, and outcomes reported. We intended to extract data to allow an intention-to-treat analysis (all the participants analysed according to the intervention to which they were originally allocated whether they received it or not). This was not possible but may be attempted in future updates. Where the numbers randomized and the numbers analysed for each outcome were inconsistent, we calculated the percentage loss to follow up and recorded this information in a table for methodological quality (Table 01). For binary outcomes, we recorded the number of participants experiencing the event in each group of the trial. For continuous outcomes, we extracted arithmetic means and standard deviations. Where geometric means were reported, we extracted and recorded this information. We also tried to extract confidence intervals or standard deviations on the log scale.

Data analysis

We grouped studies by the main comparator interventions, for example, albendazole versus placebo. Within comparator groups, we stratified trials into studies of treatment in individuals and studies of mass treatment in communities. Within individual and cluster randomized groups, we combined trials in a meta-analysis, if appropriate, using a fixed effect model and Review Manager 4.2. We calculated relative risks (RR) for binary outcomes and used 95% confidence intervals.

We report medians and ranges in tables only. We assessed heterogeneity by visually inspecting forest plots and carrying out a chi-squared test for heterogeneity (statistical significance at 10% level). We used the random effects model to pool data where we detected heterogeneity. If no heterogeneity was detected we used a fixed effect model. Too few trials were available to examine heterogeneity in any more detail, but this might be possible in future updates.

DESCRIPTION OF STUDIES

Study selection

We identified 146 papers from the search strategies. Seven were published trials. Of these, we included four, which are described below and detailed in the 'Characteristics of included studies' (Sri Lanka (Jaya1993); Haiti (Beach 1999); Ghana (Dunyo 2000); India (Pani 2002)), and excluded three (Ismail 1998; Shenoy 1999; Shenoy 2002) (five publications, *see* 'Characteristics of excluded studies'). We excluded two trials because the comparison groups did not address this question, and one because it was a safety study carried out only in patients with no detectable microfilariae.

Study design

All studies were randomized, and the unit of randomization for each trial was the individual.

The length of the follow up varied from 4 months (Haiti (Beach 1999)) to 12 months (Ghana (Dunyo 2000); India (Pani 2002)) to 19 months (Sri Lanka (Jaya1993)).

Participants

A total of 2473 children and adults were randomized in the four trials, of whom 536 had detectable microfilariae. Sri Lanka (Jaya1993) and India (Pani 2002) enrolled people who were microfilariae positive and asymptomatic, Ghana (Dunyo 2000) and Haiti (Beach 1999) enrolled people who were microfilariae positive or negative at baseline. One study specifically excluded children less than six years old and pregnant women (Ghana (Dunyo 2000)).

Intervention

The trials addressed all the pre-specified comparisons: albendazole alone versus placebo (Haiti (Beach 1999); Ghana (Dunyo 2000)), albendazole alone versus DEC (Sri Lanka (Jaya1993); India (Pani

2002)), albendazole alone versus ivermectin (Haiti (Beach 1999); Ghana (Dunyo 2000)), albendazole plus DEC versus DEC (India (Pani 2002)), and albendazole plus ivermectin versus ivermectin (Haiti (Beach 1999); Ghana (Dunyo 2000)).

The dose of albendazole (400 mg) was same in all the trials. The ivermectin doses varied from 200 to 400 µg/kg in Haiti (Beach 1999) to 150 to 200µg/kg in Ghana (Dunyo 2000). Both India (Pani 2002) and Sri Lanka (Jaya1993) used the same DEC dose of 6 mg/kg.

All but one trial gave the drugs as a single treatment; Sri Lanka (Jaya1993) gave DEC daily and albendazole twice daily for 21 days.

Outcomes

All studies reported on microfilariae. Methods of measurement varied, including prevalence in 20 µl of blood (Haiti (Beach 1999)), and prevalence and density in 50 µl of blood (India (Pani 2002)), in 1 ml of blood using membrane filtration (Sri Lanka (Jaya1993)), or in 100 µl using a counting chamber (Ghana (Dunyo 2000)). The studies also expressed outcomes differently (*see* Characteristics of included studies). All four trials reported adverse events; none of the included studies determined the effect of treatment on adult worms by ultrasound scan.

Reported statistical analysis

Standard deviations or confidence intervals were not reported for microfilarial density outcomes. For this reason, we could not pool results for changes in microfilarial density; results quoted in this review are the trial authors' calculations.

Two of the trials did not clearly describe the method of calculating reductions in geometric mean microfilarial density (Sri Lanka (Jaya1993); India (Pani 2002)), but India (Pani 2002) provided further details on request. This study calculated a Williams' mean (a modification of the geometric mean to include zero counts; Basanez 1994) on the pretreatment and post-treatment microfilarial densities. Ghana (Dunyo 2000) calculated change in microfilarial density using both the Williams mean and 'area under the curve' analysis (an average intensity over the whole 12 month post-treatment period).

Haiti (Beach 1999) calculated the geometric mean microfilarial density reduction by dividing the difference between densities before and after treatment by the pretreatment microfilarial density and log-transforming the results. If pretreatment microfilarial density was less than the density after treatment, the reduction was deemed to be zero. The authors performed this adjustment to eliminate the problem of log transforming a negative value, but this method may bias estimates of treatment effectiveness as increases in microfilarial density after treatment are set to zero. For this reason, we present the pretreatment and post-treatment geometric means for each arm of their study, and percentage change using these group means.

METHODOLOGICAL QUALITY

The details of the methodological quality assessment are available in Table 01.

Generation of allocation sequence

All trials were described as randomized, but India (Pani 2002) did not describe a method of randomization, and Sri Lanka (Jaya1993) only stated that the list was predetermined and restricted.

Allocation concealment

Allocation was concealed in Haiti (Beach 1999) and India (Pani 2002) by using a third party in the allocation process, but was unclear in the other trials.

Blinding

Three of the trials were double blind (Ghana (Dunyo 2000); Haiti (Beach 1999); India (Pani 2002)), but blinding was not mentioned in the fourth study (Sri Lanka (Jaya1993)).

Completeness of follow up

Losses to follow up were significant in three of the studies. In Ghana (Dunyo 2000), 1181 (82.9%) of the 1425 participants were re-examined at 12 months. Losses were similar in the 340 microfilariae-positive participants enrolled in this study, 67 of these (20%) were lost to follow up. Haiti (Beach 1999) excluded 380 out of 965 randomized participants (39%) who did not have both pretreatment and post-treatment blood examinations. However, there were few losses ($n = 3$) among the 113 microfilariae-positive participants at baseline. In Sri Lanka (Jaya1993), 6 of 16 men allocated to albendazole (37.5% lost to follow up), and 3 of 13 to DEC (23% lost to follow up) were lost to follow up by 15 to 19 months. India (Pani 2002) reported no losses to follow up.

RESULTS

Albendazole versus placebo

In all participants (both microfilariae positive or negative at baseline)

Microfilaraemia

Haiti (Beach 1999) did not detect a statistical difference in prevalence of microfilaraemia for albendazole (22/145) versus placebo (20/139) (RR 1.05, 95% CI 0.60 to 1.84; Graph 01-01).

Antigenaemia prevalence

Ghana (Dunyo 2000) reported no statistical difference in the numbers circulating filarial antigen positive at baseline or 12 months (albendazole 105 at baseline, 110 at 12 months; placebo 103 at baseline, 102 at 12 months).

Clinical disease

At 12 months post-treatment Ghana (Dunyo 2000) detected no statistical difference in the development of hydrocoele between albendazole (1/129) and placebo (1/126) (RR 0.98, 95% CI 0.06 to

15.45; Graph 01-02). No new cases of acute filariasis and leg lymphoedema were observed. Similarly, there were no differences in improvement of symptoms in lymphoedema between the albendazole group (3/13) and placebo group (2/9) (RR 1.04, 95% CI 0.22 to 5.01; Graph 01-03), or in hydrocoele between the albendazole group (3/8) and placebo group (5/10) (RR 0.75, 95% CI 0.25 to 2.23; Graph 01-03). No statistically significant differences were detected, but the studies lacked power for clinical outcomes, so clinically important differences cannot be ruled out.

Adverse events

Ghana (Dunyo 2000) did not detect a difference in systemic adverse events between the albendazole group (31/336) compared to placebo group (33/314) (RR 0.88, 95% CI 0.55 to 1.40; Graph 01-04). No local or severe adverse events were reported. Table 06 displays frequency of specific adverse events.

In participants microfilariae positive at baseline (microfilariae negative excluded)

Microfilaraemia

Haiti (Beach 1999) found no difference in prevalence between albendazole (22/29) and placebo (20/29) at four months (RR 1.10, 95% CI 0.80 to 1.51). Similarly, Ghana (Dunyo 2000) found no difference in prevalence at 12 months (62/71 albendazole, 62/66 placebo) (RR 0.93, 95% CI 0.83 to 1.04). A combined estimate from these two trials shows no difference in microfilaraemia between albendazole and placebo (RR 0.97, 95% CI 0.87 to 1.09, $n = 195$; Graph 01-05).

Microfilarial density (percentage reduction)

Haiti (Beach 1999) estimated the reduction in geometric mean microfilarial density. The reductions were 63.8% (14.1 to 5.1) in the albendazole group, and 43.0% (9.3 to 5.3) in the placebo group at four months (not statistically significant). Ghana (Dunyo 2000) reported geometric mean microfilarial density at baseline and 12 months (with percentage reduction). The density decreased from 798 to 251 (68.5%) in the albendazole group compared to 971 to 845 (13.0%) in the placebo group, but this was not statistically significant ($P = 0.10$). An 'area under the curve' analysis from this study found an increase in microfilariae geometric mean intensity in the placebo group from 2536 to 2740 (8.4% increase), and a decrease in the albendazole group from 1535 to 1233 (19.7%); again this was not statistically significant ($P = 0.12$). The latter analysis was limited to those with complete data collection and microfilarial density of over 100 microfilariae/ μ l at baseline (*see* Table 04).

Antigen density (percentage change)

Ghana (Dunyo 2000) reported that reported that unit geometric mean microfilarial density (measured by circulating filarial antigen) had increased by 47.5% of the pretreatment level in the placebo group, but decreased to 83.1% of the pretreatment level in the albendazole group, but this difference was not statistically significant ($P = 0.11$) (Table 05).

Albendazole versus ivermectin

In all participants (both microfilariae positive or negative at baseline)

Microfilaraemia

Haiti (Beach 1999) did not demonstrate a difference in microfilarial prevalence at follow up between groups allocated to albendazole (22/145) or ivermectin (20/150) (RR 1.14, 95% CI 0.65 to 1.99; Graph 02-01).

Antigenaemia prevalence

Ghana (Dunyo 2000) reported no difference in the numbers circulating filarial antigen positive at baseline or 12 months (albendazole: 105 at baseline, 110 at 12 months; ivermectin: 99 at baseline, 101 at 12 months).

Clinical disease

Ghana (Dunyo 2000) found no differences in (1) the risk of developing hydrocoele in the albendazole (1/129) and ivermectin (1/133) groups (RR 1.03, 95% CI 0.07 to 16.31; Graph 02-02); (2) improvements in lymphoedema in the albendazole (3/13) and ivermectin (2/13) groups (RR 1.50, 95% CI 0.30 to 7.55; Graph 02-03); and (3) improvements in hydrocoele in the albendazole (3/8) and ivermectin (2/9) groups (RR 1.69, 95% CI 0.37 to 7.67; Graph 02-03). However, sample sizes were small and confidence intervals wide.

Adverse events

Ghana (Dunyo 2000) detected no difference in systemic adverse events between the albendazole (31/336) and ivermectin (36/295) groups (RR 0.76, 95% CI 0.48 to 1.19; Graph 02-04).

In participants microfilariae positive at baseline (microfilariae negative excluded)

Microfilaraemia

Haiti (Beach 1999) reports microfilarial prevalence at 4 months follow up: 22/29 in the albendazole group and 17/28 in the ivermectin group (RR 0.80, 95% CI 0.56 to 1.15; Graph 02-05). Ghana (Dunyo 2000) also reported this outcome: 62/71 in the albendazole group and 52/70 in the ivermectin group (RR 0.85, 95% CI .72 to 1.00; Graph 02-05). Pooling the two studies, albendazole was slightly worse at clearing microfilariae, but this only just reached statistical significance (RR 0.84, 95% CI 0.72 to 0.98; Graph 02-05).

Microfilarial density (percentage reduction)

Haiti (Beach 1999) reported on the percentage reduction in geometric mean microfilarial density. The values at baseline and four months follow up (with percentage reductions) were 14.1 and 5.1 (63.8% reduction) for albendazole, and 15.5 to 1.5 (90.2% reduction) for ivermectin. No test of statistical significance was applied. Ghana (Dunyo 2000) measured mean values at baseline and 12 months follow up (with percentage reductions). For albendazole, this was from 798 to 251 (68.5% reduction); and for ivermectin, from 640 to 124 (80.6% reduction); no statistical significance test

was reported. An 'area under the curve' analysis from this study found a decrease in the albendazole group (from 1535 to 1233, 19.7%) and in the ivermectin group (from 1731 to 759, 56.2%). The latter analysis was limited to those with complete data collection and microfilarial density of over 100 microfilariae/ μ l at baseline (see Table 04).

Antigenaemia density (percentage reduction)

Ghana (Dunyo 2000) reported that unit geometric mean microfilarial density (measured by circulating filarial antigen) had decreased to 83.1% of the pretreatment level in the albendazole group, and 70.3% in the ivermectin group (no statistical test applied) (Table 05).

Albendazole plus ivermectin versus ivermectin

In all participants (both microfilariae positive or negative at baseline)

Microfilaraemia

Haiti (Beach 1999) estimated a statistically significant 65% reduction in microfilarial prevalence for the combination (7/151) compared to ivermectin alone (20/150) (RR 0.35, 95% CI 0.15 to 0.80; Graph 03-01).

Antigen prevalence

Ghana (Dunyo 2000) reported no difference in the numbers of participants positive for circulating filarial antigen at baseline or 12 months (albendazole plus ivermectin: n = 121 at baseline, n = 122 at 12 months; ivermectin n = 99 at baseline, n = 101 at 12 months).

Clinical disease

Ghana (Dunyo 2000) found no difference in new cases of hydrocoele between the combination treatment (2/147) compared to ivermectin (1/133) (RR 1.81, 95% CI 0.17 to 19.73; Graph 03-02). This study also observed no differences in improvement in lymphoedema between the combination (2/13) and ivermectin (2/13) (RR 1.00, 95% CI 0.16 to 6.07; Graph 03-03), and no differences between combination treatment (4/10) and ivermectin (2/9) in hydrocoele (RR 1.80, 95% CI 0.43 to 7.59; Graph 03-03). Again, the studies were not designed to detect changes in clinical outcomes, therefore confidence intervals are very wide.

Adverse events

Ghana (Dunyo 2000) recorded more adverse events with the combination treatment (47/332) compared to ivermectin (36/295), but this was not statistically significant (RR 1.16, CI 0.77 to 1.74; Graph 03-04). Table 06 displays the occurrence of specific adverse events.

In participants microfilariae positive at baseline (microfilariae negative excluded)

Microfilaraemia

Haiti (Beach 1999) reported a 73% reduction in microfilariae for the combination of albendazole and ivermectin (4/24) compared to ivermectin alone (17/28) at four months (RR 0.27, 95%

CI 0.11 to 0.70, random effects model; Graph 03-05). However, Ghana (Dunyo 2000) found no difference between the combination (58/75) and ivermectin (52/70) (RR 1.04, 95% CI 0.87 to 1.25, random effects model; Graph 03-05). The pooled RR indicated no significant difference for the combination compared to ivermectin alone, but the confidence intervals are wide. The RR is 0.57 (95% CI 0.13 to 2.48) using the random effects model and 0.87 (95% CI 0.71 to 1.06) using the fixed effect model (Graph 03-05).

Microfilarial density (percentage reduction)

Haiti (Beach 1999) reported a reduction in geometric mean microfilarial density in the combination group from 13.7 to 0.3 (97.8%) compared to 15.5 to 1.5 (90.2%) in the ivermectin group at four months ($P < 0.05$). Ghana (Dunyo 2000) reported a reduction in geometric mean microfilarial density in both groups after 12 months: from 614 to 78 (87.3% reduction) in the combination group compared to a change from 640 to 124 (80.6% reduction) in the ivermectin group. This was not statistically significant ($P = 0.80$). An 'area under the curve' analysis from this study found a decrease in the combination group (from 1280 to 393, 69.3%) and the ivermectin group (from 1731 to 759, 56.2%); this difference was not statistically significant ($P = 0.26$). The latter analysis was limited to those with complete data collection and microfilarial density of over 100 microfilariae/ μ l at baseline (see Table 04).

Albendazole versus DEC

Two very small studies compared albendazole to DEC. Sri Lanka (Jaya1993) compared albendazole ($n = 16$) to DEC ($n = 13$) and attempted to follow up participants for up to 19 months. They reported that all participants in this extended follow up lived nearby and had received treatment in addition to the study intervention, but the nature of this is unclear. India (Pani 2002) compared albendazole alone ($n = 19$) and DEC ($n = 17$), with albendazole and DEC co-administered ($n = 18$). All participants were microfilariae positive at baseline.

Microfilaraemia

India (Pani 2002) reported no statistically significant difference in microfilarial prevalence at 360 days (14/19 on albendazole compared to 14/17 on DEC). Sri Lanka (Jaya1993) stated that 85% of the participants treated with albendazole (numerator and denominator unclear) and 67% of the participants treated with DEC (8/12) still had detectable microfilariae at six months. At the extended follow up of 15 to 19 months, 50% of participants in both groups were microfilariae positive (5/10 on both albendazole and DEC), but a substantial proportion of participants had been lost to follow up. The data are displayed graphically but should be viewed with caution (Graph 04-01).

Antigenaemia prevalence

India (Pani 2002) reported no statistically significant difference in prevalence of filarial antigenaemia at any point during the study ($P > 0.05$). The percentage reduction was 83% on albendazole and 87% on DEC (by immuno-chromatographic card test), and 83%

albendazole and 80% DEC (by Og4C3 (ELISA test kit) (Table 03).

Microfilarial density (percentage reduction)

India (Pani 2002) reported no statistically significant difference in percentage reductions in geometric mean microfilarial density at any of the time points when this was measured (days 3, 7, and 360). The percentage reductions at 360 days compared to pre-therapy values were 97.4% for albendazole and 89.6% for DEC. However, microfilarial density appeared to fall faster during the first 7 days on DEC compared to albendazole (Table 03).

Sri Lanka (Jaya1993) also found large reductions in microfilarial density at six months for both treatment groups; the geometric mean microfilarial density had fallen to 1.91% of its initial value for those treated with albendazole and 0.81% for those treated with DEC. At the extended follow up (15 to 19 months), there was no statistically significant difference in the geometric mean microfilarial densities (3 for albendazole and 2 for DEC) (Table 03). Similarly to India (Pani 2002), microfilarial density appeared to fall faster during the first 28 days on DEC compared to albendazole.

Antigenaemia density

India (Pani 2002) reported statistically significant reductions in mean optical antigen density by Og4C3 assay in both groups at 360 days (reduction of 0.41 on albendazole, $P < 0.0001$ for the pre-intervention value compared to the post-intervention value, 0.32 on DEC; $P < 0.0001$ for pre-intervention versus post-intervention value) (Table 05).

Adverse events

India (Pani 2002) reported no severe adverse events in any group. Those observed were transient (not lasting beyond 6 days) and included fever, myalgia, and headache. There was no difference in the proportion reporting any systemic adverse events between albendazole (8/19, 42.1%) and DEC (9/17, 52.9%) (RR 0.80, 95% CI 0.40 to 1.59; Graph 04-02). The authors used a score for assessing adverse reactions. The mean score of adverse reaction intensity was lower for albendazole (1.8, standard deviation 3.0) compared to DEC (5.6, standard deviation 7.1) ($P < 0.05$). However, the validity and clinical significance of this scoring system is uncertain. In Sri Lanka (Jaya1993), 11 of 15 participants receiving the full treatment regimen for albendazole developed "scrotal syndrome"; this was classified as 'severe' for two men, moderate for two, and mild for the other 7. None of the participants on DEC developed similar symptoms (RR 12.19, 95% CI 0.77 to 194.03; Graph 04-03). One participant on DEC had fever, right hypochondrial pain, and repeated vomiting, and was withdrawn from the study. However, the drug doses were much higher in this trial than in the other three. Participants were given albendazole twice a day, or DEC once a day for three weeks. All other trials tested a single dose of albendazole plus DEC or ivermectin.

Albendazole plus DEC versus DEC

Microfilaraemia

India (Pani 2002) found no statistically significant difference in microfilarial prevalence at 360 days (13/18 on albendazole plus DEC compared to 14/17 on DEC; Graph 05-01).

Antigenaemia prevalence

India (Pani 2002) reported no statistically significant difference in prevalence of filarial antigenaemia at any point during the study ($P > 0.05$). The percentage reduction was 75% on albendazole plus DEC compared to 87% on DEC (by immuno-chromatographic card test), and 81% on albendazole plus DEC compared to 80% on DEC (by Og4C3) (Table 03).

Microfilarial density (percentage reduction)

Again, there was no difference in percentage reductions in geometric mean microfilarial density. The percentage reductions at 360 days compared with pre-therapy values were 95.4% for albendazole and 89.6% for DEC (Table 04).

Antigenaemia density

There were statistically significant reductions in mean optical antigen density by Og4C3 assay in both groups at 360 days in India (Pani 2002) (reduction of 0.40 on albendazole plus DEC, $P < 0.0001$ for pre-intervention compared to post-intervention value, 0.32 on DEC; $P < 0.0001$ for pre-intervention versus post-intervention value) (Table 05).

Adverse events

India (Pani 2002) reported no difference in the proportion reporting any systemic adverse events between albendazole plus DEC (11/18, 61.1%) and DEC alone (9/17, 52.9%) (RR 1.15, 95% CI 0.65 to 2.06; Graph 05-02), or in the mean score of adverse reaction intensity for albendazole plus DEC (6.7, standard deviation 6.6) compared to DEC alone (5.6, standard deviation 7.1).

DISCUSSION

The review was designed to assess the effects of albendazole alone or in combination with currently recommended antifilarial drugs, ivermectin, or DEC. Although the review has considered the effects of albendazole alone, the main interest and strategy of the 'Global Alliance to Eliminate Lymphatic Filariasis' is in the effectiveness of combinations of different antifilarial drugs (Ismail 1998; Shenoy 1999). Of particular interest is the effectiveness of adding albendazole (thought to be macrofilaricidal) to single dose regimens of ivermectin (thought to be mainly microfilaricidal) or DEC (possibly both microfilaricidal and macrofilaricidal) (CDS/FIL 1998; Ottesen 1999).

All the included studies were designed primarily to assess the effectiveness of albendazole to treat individuals; none have explicitly considered its effects on transmission in whole communities. We identified only four studies, and most are small. All were described as randomized but had other important limitations. In particular,

losses to follow up were very high (above 20%) in all studies except for India (Pani 2002), and this may lead to imbalances in the comparison groups. Differences in design (microfilariae-positive participants only versus microfilariae-positive and microfilariae-negative participants at baseline, variable outcome measurement and reporting, and length of follow up) made it difficult to compare the studies. In particular, some trials report outcomes mainly for those who are microfilariae positive at baseline (Ghana (Dunyo 2000)). Outcomes for all participants in the trial, regardless of baseline microfilarial status, would be preferable in assessing the community impact of mass treatment strategies. Only two of the studies report changes in antigenaemia prevalence or density in addition to microfilarial prevalence and density (Ghana (Dunyo 2000); India (Pani 2002)). However, there was broad agreement between changes in both these outcome measures in these two studies. None of the studies objectively examined the effects of antifilarial medication on the viability of adult worms. As adult worms are responsible for the production of microfilariae, the extent to which antifilarial drugs affect worm viability is an important outcome.

Albendazole alone was not effective in reducing microfilarial prevalence (Haiti (Beach 1999); Ghana (Dunyo 2000)), or circulating filarial antigens (Ghana (Dunyo 2000)), compared to placebo. Ivermectin appears more effective than albendazole in both these trials, and a meta-analysis indicates a marginal but statistically significant 16% reduction in the RR of microfilarial prevalence after treatment for those who were microfilariae positive at baseline in favour of ivermectin.

In one trial, the combination of albendazole and ivermectin was better than ivermectin alone after four months follow up (Haiti (Beach 1999)), but in the other trial in which this combination was examined they were about the same after 12 months follow up (Ghana (Dunyo 2000)). The lack of measurements at similar intervals made it impossible to know if the results were substantially alike. It is possible that by 12 months microfilariae levels had risen sufficiently to dampen the actual effect of the drugs in the Ghana (Dunyo 2000). The dose of ivermectin was also lower in Ghana (Dunyo 2000) than in Haiti (Beach 1999). Investigators in the two trials used different techniques to assess microfilariae: thick film method in 20 μ l of blood with measurement at night in Haiti (Beach 1999); and the counting chamber method in 100 μ l of blood with measurement during the day in Ghana (Dunyo 2000).

Two very small trials compared albendazole to DEC (India (Pani 2002); Sri Lanka (Jaya1993)). Neither found any statistically significant differences in microfilarial prevalence or density at any of the time points measured. Sri Lanka (Jaya1993) included an extended follow up at 15 to 19 months. There was no statistical difference in microfilarial prevalence or density between the two groups at this point, but the numbers were very small and a high proportion had been lost to follow up. India (Pani 2002) also

found no statistically significant differences between albendazole alone, DEC alone, and albendazole plus DEC at one year follow up. Follow up was complete, but this trial lacked statistical power.

Although all trials provided data on geometric mean microfilarial density, lack of reporting of standard deviations or confidence intervals made it impossible to include these results in a meta-analysis. A reduction in geometric mean microfilarial density was observed for all treatments including placebo, and the reduction appeared greater for active treatments (albendazole, DEC, and ivermectin), but tests of statistical significance were not always carried out or reported.

The effect of treatment on clinical disease was not remarkable in any of the comparison groups. This is not surprising as effect sizes for clinical outcomes were small and the studies were not powered to detect small clinical benefits.

No severe adverse events or localized reactions were reported in three of the trials (Haiti (Beach 1999); Ghana (Dunyo 2000); India (Pani 2002)). Sri Lanka (Jaya 1993) found a very high incidence of "scrotal syndrome" among those treated with albendazole, but the doses of both albendazole and DEC were very much higher than in the other trials. One trial reported that people in the ivermectin group were more likely to report any systemic adverse event compared to albendazole, but this was not significant (Ghana (Dunyo 2000)). One trial reported a significantly lower intensity of adverse events in the albendazole group, compared to DEC, or albendazole combined with DEC, but no statistical difference in the proportions reporting any adverse events (Ghana (Dunyo 2000)). The death of worms is associated with the development of adverse events, so differences in the reporting of adverse events between albendazole, ivermectin, or DEC groups may reflect differences in the macrofilaricidal properties of the drugs (Addiss 2000). However, the studies lack statistical power to identify differences in reporting of adverse events.

AUTHORS' CONCLUSIONS

Implications for practice

Based on limited data, the evidence suggests that albendazole alone is not better than placebo, ivermectin, or DEC at clearing blood microfilariae. Results from two studies that compared albendazole plus ivermectin to ivermectin alone were inconsistent. There was little difference in the effects detected with albendazole alone, DEC alone, or albendazole co-administered with DEC from two very small studies. All the studies were underpowered to assess the effects of albendazole – alone or in combination – on morbidity or adverse events. Five ongoing trials are examining the benefits of adding albendazole to ivermectin or DEC.

The conclusions of this review are based on trials that have only randomized and treated individuals. Therefore they should be cau-

tiously extrapolated to large scale, population-based mass drug administration programmes.

Implications for research

We found only limited data. Further large well-designed studies are required. For example, studies to:

- compare the effects of albendazole alone, albendazole plus DEC, and albendazole plus ivermectin on treating and controlling lymphatic filariasis;
- measure the impact of albendazole in mass drug administration campaigns;
- evaluate other interventions (against the parasite or the vector) to augment mass drug administration.

Complete clearance of blood microfilariae theoretically represents the most reliable strategy for interrupting transmission. But this may be difficult to achieve in practice, as apart from DEC, currently available antifilarial drugs mainly act on microfilariae with no demonstrable macrofilaricidal activity. A drug that kills both microfilariae and adults is clearly ideal, and there is an argument for more research on the effects of antifilarial drugs on the adult worm. This could be assessed objectively, as with ultrasound detection, on a relatively small number of infected individuals.

It is also not known how low microfilarial densities need to fall in order to successfully interrupt transmission from the various vector species. As microfilaraemia is an intermediate outcome reflecting infectivity of the human host, it is important to assess comparative effectiveness of drugs that aim to interrupt transmission. Techniques for assessing microfilariae in blood and outcome measures for microfilarial densities need to be standardized with complete reporting of means and standard deviations.

POTENTIAL CONFLICT OF INTEREST

Henry Ejere: The Lymphatic Filariasis Support Centre based in the Liverpool School of Tropical Medicine paid Henry Ejere's salary. The Department for International Development, UK and Glaxo-SmithKline fund the Lymphatic Filariasis Support Centre. Dr Addiss is an author on one of the trials. Julia Critchley, Paul Garner, Hellen Gelband, Carrol Gamble: none known.

ACKNOWLEDGEMENTS

None stated.

SOURCES OF SUPPORT

External sources of support

- Department for International Development UK
- GlaxoSmithKline UK

Internal sources of support

- Lymphatic Filariasis Support Centre, Liverpool School of Tropical Medicine UK

REFERENCES

References to studies included in this review

Ghana (Dunyo 2000) {published data only}

*Dunyo SK, Nkrumah FK, Simonsen PE. Single-dose treatment of *Wuchereria bancrofti* infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2000;**94**(4):437–43.

Dunyo SK, Nkrumah FK, Simonsen PE. A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2000;**94**(2):205–11.

Dunyo SK, Simonsen PE. Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis. *Transactions of the Royal Society for Tropical Medicine and Hygiene* 2002;**96**(2):189–92.

Haiti (Beach 1999) {published data only}

Addiss DG, Beach MJ, Streit TG, Lutwick S, LeConte FH, Lafontant JG, et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for *Wuchereria bancrofti* microfilaraemia in Haitian children. *Lancet* 1997;**350**(9076):480–4.

*Beach MJ, Streit TG, Addiss DG, Prospere R, Roberts JM, Lammie PJ. Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and *Wuchereria bancrofti* infections in Haitian school children. *American Journal of Tropical Medicine and Hygiene* 1999;**60**(3):479–86.

India (Pani 2002) {published data only}

Pani SP, Reddy GS, Das LK, Vanamail P, Hoti SL, Ramesh J, et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co-administration of albendazole with DEC in the clearance of *Wuchereria bancrofti* in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital-base study. *Filaria Journal* 2002;**1**:1.

Sri Lanka (Jaya1993) {published data only}

Jayakody RL, De Silva CS, Weerasinghe WM. Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions. *Tropical Biomedicine* 1993;**10**:19–24.

References to studies excluded from this review

Dunyo 2002

Dunyo SK, Simonsen PE. Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow-up after re-treatment with the combination. *Transaction of the Royal Society of Tropical Medicine and Hygiene* 2002;**96**(2):189–92.

Ismail 1998

*Ismail MM, Jayakody RL, Weil GJ, Nirmalan N, Jayasinghe KS, Abeyewickrema W, et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1998;**92**(1):94–7.

Ismail 2001

Ismail MM, Jayakody RL, Weil GJ, Fernando D, De Silva MSG, De Silva GAC, et al. Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2001;**95**(3):332–5.

Shenoy 1999

Shenoy RK, Dalia S, John A, Suma TK, Kumaraswami V. Treatment of the microfilaraemia of asymptomatic brugian filariasis with single doses of ivermectin, diethylcarbamazine or albendazole, in various combinations. *Annals of Tropical Medicine and Parasitology* 1999;**93**(6):643–51.

Shenoy 2000

Shenoy RK, John A, Babu BS, Suma TK, Kumaraswami V. Two-year follow-up of the microfilaraemia of asymptomatic brugian filariasis, after treatment with two, annual, single doses of ivermectin, diethylcarbamazine and albendazole, in various combinations. *Annals of Tropical Medicine and Parasitology* 2000;**94**(6):607–14.

Shenoy 2002

Shenoy RK, Suma TK, John A, Arun SR, Kumaraswami V, Fleckenstein LL, et al. The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole. *Annals of Tropical Medicine and Parasitology* 2002;**96**(6):603–14.

References to studies awaiting assessment

Simonsen 2004

Simonsen PE, Magesa SM, Dunyo SK, Malecela-Lazaro MN, Michael E. The effect of single dose ivermectin alone or in combination with albendazole on *Wuchereria bancrofti* infection in primary

school children in Tanzania. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2004;**98**(8):462–72.

References to ongoing studies

Beach (ongoing)

No details.. Ongoing study No details..

Beach MJ.

Dahoma (ongoing)

Assessment of safety and efficacy of ivermectin and albendazole co-administration.. Ongoing study No details..

Das (ongoing)

Cluster randomized trial of ivermectin, DEC, and albendazole.. Ongoing study No details..

Kshirsagar (ongoing)

Assessment of safety, tolerability, efficacy, and population pharmacokinetics of diethylcarbamazine and albendazole co-administration in a field study in India.. Ongoing study No details..

Makunde (ongoing)

Assessment of safety, tolerability, and efficacy of albendazole alone or in combination with ivermectin in Tanzania.. Ongoing study No details..

Makunde WH, Kamugisha LM, Massaga JJ, Salum FM, Makunde RW, Savael ZX, Akida J, Salum FM, Taylor MJ. Treatment of coinfection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis. *Filaria Journal* In press.

Additional references

Addiss 2000

Addiss D, Dreyer G. Treatment of lymphatic filariasis. In: Nutman BT, editor(s). *Lymphatic filariasis*. London: Imperial College Press, 2000:151–99.

Andrade 1995

Andrade LD, Medeiros Z, Pires ML, Pimentel A, Rocha A, Figueredo-Silva J, et al. Comparative efficacy of three different diethylcarbamazine regimens in lymphatic filariasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1995;**89**(3):319–21.

Barat 1997

Barat LM, Bloland PB. Drug resistance among malaria and other parasites. *Infectious Disease Clinics of North America* 1997;**11**:969–87.

Basanez 1994

Basanez MG, Boussinesq M, Prod'hon J, Frontado H, Villamizar NJ, Medley GF, et al. Density-dependent processes in the transmission of human onchocerciasis: intensity of microfilariae in the skin and their uptake by the simuliid host. *Parasitology* 1994;**108**(Pt 1):115–27.

Burkot 2002

Burkot TR, Taleo G, Toeaso V, Ichimoir K. Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities. *Annals of Tropical Medicine and Parasitology* 2002;**96** Suppl 2:61–9.

Cao 1997

Cao WC, Van der Ploeg CP, Plaisier AP, van der Sivera Sluijs IJ, Habbema JD. Ivermectin for the chemotherapy of bancroftian filaria-

sis: a meta-analysis of the effect of single treatment. *Tropical Medicine and International Health* 1997;**2**(4):393–403.

Cartel 1990

Cartel JL, Sechan Y, Boutin JP, Celerier P, Plichart R, Roux JF. Ivermectin for treatment of bancroftian filariasis French Polynesia: efficacy in man, effect on transmission by vector *Aedes polynesiensis*. *Tropical Medicine and Parasitology* 1990;**41**(3):241–4.

CDS/FIL 1998

Filariasis Elimination Programme (CDS/FIL) Division of Control of Tropical Diseases, Communicable Diseases. *Report from informal consultation on albendazole research findings in lymphatic filariasis (closed document)*. Geneva: World Health Organization, 1998.

Clarke 2003

Clarke M, Oxman A, editors. Optimal search strategy. *Cochrane Reviewers' Handbook* 4.2 [updated March 2003]; Appendix 5C. In: *The Cochrane Library*. The Cochrane Collaboration. Chichester, UK: John Wiley & Sons, Ltd; 2003, issue 3

Coutinho 1994

Coutinho AD, Dreyer G, Medeiros Z, Lopes E, Machado G, Galdino E, et al. Ivermectin treatment of bancroftian filariasis in Recife, Brazil. *American Journal of Tropical Medicine and Hygiene* 1994;**50**(3):339–48.

Dreyer 1994

Dreyer G, Pires ML, Andrade LD, Lopes E, Medeiros Z, Tenorio J, et al. Tolerance of diethylcarbamazine by microfilaraemic and amicrofilaraemic individuals in an endemic area of Bancroftian filariasis, Recife, Brazil. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1994;**88**(2):232–6.

Dreyer 1995

Dreyer G, Amaral F, Noroes J, Medeiro Z, Addiss D. A new tool to assess in vivo the adulticidal efficacy of antifilarial drugs for bancroftian filariasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1995;**89**(2):225–6.

Dreyer 1996

Dreyer G, Addiss D, Noroes J, Amaral F, Rocha A, Coutinho A. Ultrasonographic assessment of the adulticidal efficacy of repeat high-dose ivermectin in bancroftian filariasis. *Tropical Medicine and International Health* 1996;**1**(4):427–32.

Dreyer 2000

Dreyer G, Noroes J, Figueredo-Silva, Piessens WF. Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. *Parasitology Today* 2000;**16**(12):544–8.

Eberhard 1989

Eberhard ML, Lammie PJ, Roberts JM, Lowrie RC Jr. Effectiveness of spaced doses of diethylcarbamazine citrate for the control of bancroftian filariasis. *Tropical Medicine and Parasitology* 1989;**40**(2): 111–3.

FGN 1996

The Filarial Genome Network. Biology and epidemiology of filarial nematodes. <http://www.math.smith.edu/~sawlab/fgn/pnb/filbio.html> 1996 (accessed 3 September 2001).

Figueredo-Silva 1996

Figueredo-Silva J, Jungmann P, Noroes J, Piessens WF, Coutinho A, Brito C, et al. Histological evidence for adulticidal effect of low

- doses of diethylcarbamazine in bancroftian filariasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1996;**90**(2):192–4.
- Geerts 2001**
Geerts S, Gryseels B. Anthelmintic resistance in human helminths: a review. *Tropical Medicine and International Health* 2001;**6**(11):915–21.
- Gelband 1994**
Gelband H. Diethylcarbamazine salt in the control of lymphatic filariasis. *American Journal of Tropical Medicine* 1994;**50**(6):655–62.
- GSK 2003**
GlaxoSmithKline. Lymphatic filariasis programme: eliminating lymphatic filariasis. www.gsk.com/filariasis/eliminating.htm (accessed October 2002).
- Horton 2000**
Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. *Parasitology* 2000;**121** Suppl:113–32.
- Juni 2001**
Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ* 2001;**323**(7303):42–6.
- Mahoney 1971**
Mahoney LE, Kessel JF. Treatment failure in filariasis mass treatment programmes. *Bulletin of the World Health Organization* 1971;**45**(1):35–42.
- Meyrowitsch 1995**
Meroywitsch DW, Simonsen PE, Makunde WH. A 16-year follow-up study on bancroftian filariasis in three communities of north-eastern Tanzania. *Annals of Tropical Medicine and Parasitology* 1995;**89**(6):665–75.
- Michael 1996**
Michael E, Bundy DAP, Grenfell BT. Re-assessing the global prevalence and distribution of lymphatic filariasis. *Parasitology* 1996;**112** (Pt 4):409–28.
- Noroës 1997**
Noroës J, Dreyer G, Santos A, Mendes VG, Medeiros Z, Addiss D. Assessment of the efficacy of diethylcarbamazine on adult *Wuchereria bancrofti* in vivo. *Transactions of the Royal Society Tropical Medicine and Hygiene* 1997;**91**(1):78–81.
- Ottesen 1997**
Ottesen EA, Duke BOL, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. *Bulletin of the World Health Organization* 1997;**75**(6):491–503.
- Ottesen 1999**
Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. *Parasitology Today* 1999;**15**(9):382–6.
- Pichon 2002**
Pichon G. Limitation and facilitation in the vectors and other aspects of the dynamics of filarial transmission: the need for vector control against *Anopheles*-transmitted filariasis. *Annals of Tropical Medicine and Parasitology* 2002;**96** Suppl 2:143–52.
- Review Manager 4.1**
. Review Manager (RevMan). 4.1 for Windows Edition. Oxford, England: The Cochrane Collaboration, 2000. CD-ROM and Internet.
- Review Manager 4.2**
. Review Manager (RevMan). 4.2 for Windows Edition. Oxford, England: The Cochrane Collaboration, 2002. CD-ROM and Internet.
- Scott 2000**
Scott AL. Lymphatic-dwelling filariae. In: Nutman BT, editor(s). *Lymphatic filariasis*. London: Imperial College Press, 2000:5–39.
- Simonsen 1995**
Simonsen PE, Meyrowitsch DW, Makunde WH, Magnussen P. Selective diethylcarbamazine chemotherapy for control of bancroftian filariasis in two communities of Tanzania: compared efficacy of a standard dose treatment and two semi-annual single dose treatments. *American Journal of Tropical Medicine and Hygiene* 1995;**53**(3):267–72.
- Simonsen 1997**
Simonsen PE, Niemann L, Meyrowitsch DW. *Wuchereria bancrofti* in Tanzania: microfilarial periodicity and effect of blood sampling time on microfilarial intensities. *Tropical Medicine and International Health* 1997;**2**(2):153–8.
- Taylor 2001**
Taylor MJ, Cross HF, Ford L, Makunde W, Prasad GBKS, Bilo K. Wolbachia bacteria in filarial immunity and disease. *Parasite immunology* 2001;**23**(7):401–9.
- Vanamail 1990**
Vanamail P, Subramanian S, Das PK, Pani SP, Rajagopalan PK. Estimation of fecundic life span of *Wuchereria bancrofti* from longitudinal study of human infection in an endemic area of Pondicherry (south India). *Indian Journal of Medical Research* 1990;**91**:293–7.
- Weil 1997**
Weil GJ, Lammie PJ, Weis N. The ICT filariasis test: a rapid-format antigen test for diagnosis of bancroftian filariasis. *Parasitology Today* 1997;**13**(10):401–4.
- Weil 1999**
Weil GJ, Ramzy RM, El Setouhy M, Kandil AM, Ahmed ES, Faris R. A longitudinal study of Bancroftian filariasis in the Nile Delta of Egypt: baseline data and one-year follow-up. *American Journal of Tropical Medicine and Hygiene* 1999;**61**(1):53–8.
- WHO 1984**
WHO Expert Committee on Filariasis. *Lymphatic filariasis: fourth report of the WHO Expert Committee on Filariasis [meeting held in Geneva from 31 October to 8 November 1983]*. Geneva: World Health Organization, 1984.
- WHO 2000**
World Health Organization. Lymphatic filariasis. Fact sheet 102. www.who.int/inf-fs/en/fact102.html 2000 (accessed 3 September 2001).

* Indicates the major publication for the study

TABLES

Characteristics of included studies

Study	Ghana (Dunyo 2000)
Methods	<p>Study design: randomized controlled trial.</p> <p>Follow up: 12 months.</p> <p>Method of microfilarial assessment/volume of blood: microfilariae in 100 µl of finger-prick blood using the counting chamber technique, daytime collection.</p> <p>Antigen testing by ELISA from fingerprick blood specimens.</p>
Participants	<p>Individuals (male and female) 6 to 87 years with or without <i>Wuchereria bancrofti</i>.</p> <p>1425 people randomized, of whom 340 microfilariae-positive individuals are followed up.</p>
Interventions	<p>(1) Albendazole 400 mg (88 participants).</p> <p>(2) Ivermectin 150 to 200 µg/kg (79 participants).</p> <p>(3) Albendazole plus ivermectin (90 participants).</p> <p>(4) Placebo (83 participants).</p>
Outcomes	<p>(1) Number of individuals microfilariae positive at 12 months post-treatment.</p> <p>(2) Geometric mean microfilarial density.</p> <p>(3) Percentage of pretreatment microfilarial concentration.</p> <p>(4) Geometric mean circulating filarial antigen intensity.</p> <p>(5) Geometric mean circulating filarial antigen intensity as percentage of pretreatment value.</p> <p>(6) New infections (appearance of antigenaemia).</p> <p>(7) New disease events (lymphoedema or hydrocoele).</p> <p>(8) Mortality during follow up.</p>
Notes	<p>Study location: southern Ghana (Butre, Achowa, Adjan, and Miamia villages).</p> <p>Endemicity level: 18 to 25%.</p> <p>Adjusted and unadjusted geometric mean microfilarial intensities given.</p> <p>Standard deviation not reported for geometric mean microfilarial density.</p>
Allocation concealment	B
Study	Haiti (Beach 1999)
Methods	<p>Study design: randomized controlled trial.</p> <p>Method of microfilarial assessment/volume of blood: thick smear, 20 µl of finger-prick blood.</p>
Participants	<p>Children (male and female) 5 to 11 years with <i>Wuchereria bancrofti</i> filariasis.</p> <p>Number randomized: 965 children, of whom 113 were microfilariae positive.</p>
Interventions	<p>(1) Albendazole 400 mg (244 participants).</p> <p>(2) Ivermectin 200 to 400 µg/kg (240 participants).</p> <p>(3) Albendazole plus ivermectin (245 participants).</p> <p>(4) Placebo (229 participants).</p>
Outcomes	<p>(1) Post-treatment reduction in percentage microfilarial prevalence.</p> <p>(2) Percentage reduction in geometric mean microfilarial density.</p> <p>(3) Prevalence of <i>Wuchereria bancrofti</i> among all children in each treatment group.</p>

Characteristics of included studies (Continued)

Notes Study location: Leogane, Haiti.
Endemicity level: not stated.
Standard deviation not reported for geometric mean microfilarial density.
No values reported for the albendazole group in geometric mean microfilarial percentage reduction.

Allocation concealment A

Study India (Pani 2002)

Methods Study design: randomized controlled trial.
Method of microfilarial assessment/volume of blood: not clear, 1 ml venous blood collected between 7:30 and 8:30 pm.
Antigen testing by immuno-chromatographic card test and by Og4C3 ELISA test kit on 50 µl serum.

Participants Asymptomatic volunteers (male and female) between 10 and 57 years, microfilariae positive.

Interventions (1) Albendazole 400 mg (19 participants).
(2) Diethylcarbamazine 6 mg/kg (17 participants).
(3) Albedazole plus diethylcarbamazine (18 participants).

Outcomes (1) Percentage of individuals microfilariae positive post-treatment.
(2) Percentage reduction in geometric mean microfilarial density.
(3) Percentage reduction in filarial antigen prevalence.
(4) Proportion of individuals reporting any systemic adverse event and intensity of events.

Notes Study location: Pondicherry, India.
Endemicity level: not stated.
No standard deviation reported for geometric mean microfilarial density.

Allocation concealment A

Study Sri Lanka (Jaya1993)

Methods Study design: randomized controlled trial.
Method of microfilarial assessment/volume of blood: membrane filtration for microfilariae using a Nucleopore filter with a 3 µm pore size.
Participants with mf density in night blood films > 100 microfilariae/ml at least once during previous week included.

Participants Asymptomatic men aged 18 to 65 years with *Wuchereria bancrofti* microfilariae.

Interventions (1) Albendazole 400 mg given twice daily for 21 days (16 participants).
(2) Diethylcarbamazine 6 mg/kg daily for 21 days (13 participants).

Outcomes (1) Post-treatment percentage prevalence reduction.
(2) Percentage reduction in geometric mean microfilariae density.

Notes Study location: Colombo, Sri Lanka.
Endemicity level: not stated.

Allocation concealment B

ELISA: enzyme-linked immunosorbent assay

Characteristics of excluded studies

Study	Reason for exclusion
Dunyo 2002	Update of Ghana (Dunyo 2000) following retreatment of each intervention group. Retreatment was only with albendazole plus ivermectin, hence no comparison group received ivermectin alone.
Ismail 1998	The comparison groups - albendazole versus (albendazole plus ivermectin) versus (albendazole plus diethylcarbamazine) versus (diethylcarbamazine plus ivermectin) - do not meet the inclusion criteria.
Ismail 2001	Same study as Ismail 1998 with continued follow up, and excluded for the same reasons.
Shenoy 1999	The comparison groups - albendazole versus (albendazole plus ivermectin) versus (albendazole plus diethylcarbamazine) versus (diethylcarbamazine plus ivermectin) - do not meet the inclusion criteria.
Shenoy 2000	Same study as Shenoy 1999 with follow up of individuals from previous study who were retreated. Comparison groups: (albendazole plus ivermectin) versus (albendazole plus diethylcarbamazine) versus (ivermectin plus diethylcarbamazine).
Shenoy 2002	Study of safety and tolerability of adding albendazole to diethylcarbamazine. Carried out only in patients without microfilariaemia, that is, presumably uninfected.

Characteristics of ongoing studies

Study	Beach (ongoing)
Trial name or title	No details.
Participants	No details.
Interventions	(1) Diethylcarbamazine. (2) Albendazole.
Outcomes	No details.
Starting date	No details.
Contact information	Michael Beach, CDC US. mjb3@cdc.gov
Notes	

Study	Dahoma (ongoing)
Trial name or title	Assessment of safety and efficacy of ivermectin and albendazole co-administration.
Participants	1000 participants living in an area endemic for lymphatic filariasis and soil transmitted helminths in Zanzibar, Tanzania.
Interventions	(1) Ivermectin. (2) Albendazole plus ivermectin.
Outcomes	(1) Reappearance of microfilariae at 12 months. (2) Microfilariae at 3 and 6 months. (3) Adverse drug reactions.
Starting date	No details.
Contact information	Mark Bradley, SmithKline Beecham GlaxoWellcome House West, Berkeley Avenue,

Characteristics of ongoing studies (Continued)

Greenford,
Middlesex UB6 0NN, UK
Phone: +44 (0)208 966 8543
Fax: +44 (0)208 966 8827
E-mail: mhb38319@GlaxoWellcome.co.uk

Notes

Study **Das (ongoing)**

Trial name or title Cluster randomized trial of ivermectin, DEC, and albendazole.

Participants Villages.

Interventions (1) Ivermectin
 (2) Diethylcarbamazine.
 (3) Albendazole and diethylcarbamazine.

Outcomes No details.

Starting date No details.

Contact information Dr PK Das vcrc@vsnl.com

Notes

Study **Kshirsagar (ongoing)**

Trial name or title Assessment of safety, tolerability, efficacy, and population pharmacokinetics of diethylcarbamazine and albendazole co-administration in a field study in India.

Participants 3500 participants infected or healthy in areas endemic for lymphatic filariasis in India.

Interventions (1) Diethylcarbamazine.
 (2) Albendazole plus diethylcarbamazine.

Outcomes (1) Microfilariae clearance at 3, 6, and 12 months.
 (2) Microfilariae positive at 3, 6, and 12 months.

Starting date No details.

Contact information Mark Bradley,
 SmithKline Beecham
 GlaxoWellcome House West,
 Berkeley Avenue,
 Greenford,
 Middlesex UB6 0NN, UK

 Phone: +44 (0)208 966 8543
 Fax: +44 (0)208 966 8827
 E-mail: mhb38319@GlaxoWellcome.co.uk

Notes

Study **Makunde (ongoing)**

Trial name or title Assessment of safety, tolerability, and efficacy of albendazole alone or in combination with ivermectin in Tanzania.

Participants 41 participants living in an area endemic for lymphatic filariasis.

Interventions (1) Albendazole.
 (2) Albendazole plus ivermectin.

Outcomes (1) Microfilariae counts at 6, 9, and 12 months.

Characteristics of ongoing studies (Continued)

Starting date	No details.
Contact information	Mark Taylor, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
Notes	Study in press

The names of principal investigators are used as study ID.

ADDITIONAL TABLES

Table 01. Assessment of methodological quality

Trial	Alloc. sequence	Alloc. concealment	Blinding	Follow up
Ghana (Dunyo 2000)	Adequate: computer-generated	Unclear	Double blind: identical placebos used for each group	Inadequate: 273 (80%) analysed of 340 microfilarial-positive participants randomized
Haiti (Beach 1999)	Adequate: random-number table	Adequate: concealed by third party	“Double blind” stated, although drugs were not identical, participants had no way of identifying them. Outcome assessors were blind	Inadequate: 585 analysed of 965 randomized (61%)
India (Pani 2002)	Unclear	Adequate: concealed by third party	Double blind: comparable placebo and outcome assessors blind	Adequate: implies no losses to follow up (54 analyzed out of 54 randomized)
Sri Lanka (Jaya1993)	Unclear: predetermined randomization list	Unclear: states randomization list 'restricted'	Unclear	Inadequate: 20 analysed of 29 randomized (74%)

Table 02. Microfilaraemia

Study	Intervention	No. participants	+ve at baseline	+ve post-treatment	% of baseline	% reduction
Ghana (Dunyo 2000)	Placebo	66	--	6 months: 62	93.9	
”	Albendazole	71	--	6 months: 62	87.3	
”	Ivermectin	70	--	6 months: 52	74.3	--
”	Albendazole plus ivermectin	75	--	6 months: 58	77.3	--
Haiti (Beach 1999) (only participants positive for microfilariae at baseline)	Placebo	29	--	4 months: 20	69.0	--
”	Albendazole	29	--	4 months: 22	75.9	--

Table 02. Microfilaraemia (Continued)

Study	Intervention	No. participants	+ve at baseline	+ve post-treatment	% of baseline	% reduction
"	Ivermectin	28	--	4 months: 17	60.7	--
"	Albendazole plus ivermectin	24	--	4 months: 4	16.7	--
Haiti (Beach 1999) (Participants microfilariae positive or negative at baseline)	Placebo	139	25 (18.0%)	4 months: 20 (14.4%)	--	20.0
"	Albendazole	145	26 (17.9%)	4 months: 22 (15.2%)	--	15.4
"	Ivermectin	150	26 (17.3%)	4 months: 20 (13.3%)	--	23.1
"	Albendazole plus ivermectin	151	19 (12.6%)	4 months: 7 (4.6%)	--	63.2
India (Pani 2002)	Albendazole	19	--	Day 30: none showed complete clearance Day 90: 18 (94.7%) Day 360: 14 (73.3%)	--	--
"	Diethylcarbamazine	17	--	Day 30: none showed complete clearance Day 90: 17 (100%) Day 360: 14 (82.3%)	--	--
"	Albendazole plus diethylcarbamazine	18	--	Day 30: none showed complete clearance Day 90: 18 (100%) Day 360: 13 (72.2%)	--	--
Sri Lanka (Jaya1993)	Albendazole	16	--	Day 28: 12/15 (80%) 3 months: denominator unclear 6 months: numbers unclear	--	--

Table 02. Microfilaraemia (Continued)

Study	Intervention	No. participants	+ve at baseline	+ve post-treatment	% of baseline	% reduction
				(85%) 15 to 19 months: 5/10 (50%)		
"	Diethylcarbamazine	13	--	Day 28: 7/12 (58%) 3 months: 9/12 (75%) 6 months: 8/12 (67%) 15 to 19 months: 5/10 (50%)	--	--

Table 03. Antigenaemia prevalence

Study	Outcome measure	Intervention	No. participants	% reduction	Baseline	12 months
India (Pani 2002)	Antigen positivity (immuno-chromatographic card test on 50 µl serum)	Albendazole	19	Day 360: 83	--	--
"	"	Diethylcarbamazine	17	Day 360: 87	--	--
"	"	Albendazole plus diethylcarbamazine	18	Day 360: 75	--	--
"	Antigen positivity (Og4C3 test kit on 50 µl serum)	Albendazole	19	Day 360: 83	--	--
"	"	Diethylcarbamazine	17	Day 360: 80	--	--
"	"	Albendazole plus diethylcarbamazine	18	Day 360: 81	--	--
Ghana (Dunyo 2000)	Circulating filarial antigen positive	Albendazole	--	--	105	110
"	"	Ivermectin	--	--	99	101
"	"	Albendazole plus ivermectin	--	--	121	122
"	"	Placebo	--	--	103	102

Table 04. Microfilarial density

Study	Outcome measure	Intervention	No. participants	Pretreatment	Post-treatment*	% reduction
Ghana (Dunyo 2000)	Geometric mean microfilarial density (mf/100 μ l)	Placebo	66	971	845	13.0
“	”	Albendazole	71	798	251	68.5
“	”	Ivermectin	70	640	124	80.6
“	”	Albendazole plus ivermectin	75	614	78	87.3
”	Geometric mean microfilarial density (mf/100 μ l) measured by 'area under the curve' ^{**}	Placebo	32	2536	2740	108.4 (8.4% increase)
“	”	Albendazole	42	1535	1233	19.7
“	”	Ivermectin	33	1731	759	43.8
“	”	Albendazole plus ivermectin	40	1280	393	69.3
Haiti (Beach 1999) (only participants positive for microfilariae at baseline)	Geometric mean microfilarial density (mf/20 μ l)	Placebo	29	9.3	5.3	17.2 (43.0 ^{***})
“	”	Albendazole	29	14.1	5.1	28.7 (63.8 ^{***})
“	”	Ivermectin	28	15.5	1.5	76.1 (90.2 ^{***})
“	”	Albendazole plus ivermectin	24	13.7	0.3	98.9 (97.8 ^{***})
India (Pani 2002)	Geometric mean microfilarial density (mf/50 μ l)	Albendazole	19	77.6 (range 22 to 606)	--	Day 3: 8.7 Day 7: 14.1 Day 360: 94.7
“	”	Diethylcarbamazine	17	81.3 (range 22 to 542)	--	Day 3: 26.2 Day 7: 36.7 Day 360: 89.6
“	”	Albendazole plus diethylcarbamazine	18	79.4 (range 22 to 223)	--	Day 3: 35.7 Day 7: 45.1 Day 360: 95.4
Sri Lanka	Geometric mean	Albendazole	16	633 +/- 150	3	1.91 (at 6

Table 04. Microfilarial density (Continued)

Study	Outcome measure	Intervention	No. participants	Pretreatment	Post-treatment*	% reduction
(Jaya1993)	microfilarial density (mf/1 ml)					months)
“	”	Diethylcarbamazine	13	566 +/- 120	2	0.81% (at 6 months)

FOOTNOTES

*12 months for 'Ghana (Dunyo 2000)', 4 months for 'Haiti (Beach 1999)', 15 to 19 months for 'Sri Lanka (Jaya1993)'

** Only in those individuals with over 100 mf/ μ l blood before treatment, and those examined at baseline, 3, 6, and 12 months
 ***Change in group geometric means

Table 05. Antigenaemia density

Study	Outcome measure	Intervention	No. participants	Pretreatment	Post-treatment*	% reduction
Ghana (Dunyo 2000)	Circulating filarial antigen unit (geometric mean intensity)	Placebo	103	1869	2757	147.5 (47.5% increase)
“	”	Albendazole	105	1370	1139	83.1
“	”	Ivermectin	99	1689	1187	70.3
“	”	Albendazole plus ivermectin	121	1404	834	59.4
India (Pani 2002)	Og4C3 test kit on 50 μ l serum	Albendazole	19	0.49 (standard deviation 0.16)	0.08 (standard deviation 0.17)	--
“	”	Diethylcarbamazine	17	0.39 (standard deviation 0.21)	0.07 (standard deviation 0.15)	--

Table 05. Antigenaemia density (Continued)

Study	Outcome measure	Intervention	No. participants	Pretreatment	Post-treatment*	% reduction
“	”	Albendazole plus diethylcarbamazine	18	0.47 (standard deviation 0.18)	0.07 (standard deviation 0.15)	--

FOOTNOTES

*360 days for
'India (Pani 2002)'

Table 06. Specific adverse events

Study	Adverse events	Placebo	ALB*	IVER*	ALB + IVER	DEC*	ALB + DEC
Ghana (Dunyo 2000)	Tactile fever	1/70 (1.4%)	3/80 (3.8%)	6/66 (9.1%)	16/80 (20.0%)	--	--
	Headache	0/70 (0%)	1/80 (1.3%)	7/66 (10.6%)	14/80 (17.5%)	--	--
	Muscle/joint pain	2/70 (2.9%)	3/80 (3.8%)	9/66 (13.6%)	10/80 (12.5%)	--	--
	Weakness	1/70 (1.4%)	1/80 (1.3%)	4/66 (6.1%)	7/80 (8.8%)	--	--
	Abdominal pain	1/70 (1.4%)	1/80 (1.3%)	0/66 (0%)	4/80 (5%)	--	--
	Diarrhoea	2/70 (2.9%)	0/80 (0%)	1/66 (1.5%)	2/80 (2.5%)	--	--
	Itching	0/70 (0%)	1/80 (1.3%)	2/66 (3.0%)	1/80 (1.3%)	--	--
	Rash	1/70 (1.4%)	0/80 (0%)	1/66 (1.5%)	1/80 (1.3%)	--	--
Haiti (Beach 1999) (participants microfilariae positive at baseline only)	Self-reported fever	7/29 (24%)	5/27 (19%)	--	--	--	--
	Headache	12/29 (41%)	6/27 (22%)	--	--	--	--
	Myalgias	3/29 (10%)	3/27 (11%)	--	--	--	--
	Cough	2/29 (7%)	3/27 (11%)	--	--	--	--
India (Pani 2002)	Any adverse reaction (mainly fever, headache, myalgia)	--	42.1%	--	--	52.9%	61.1%
	Mean intensity score** (standard deviation)	--	1.8 (3.0)	--	--	5.6 (7.1)	6.7 (6.6)
Sri Lanka (Jaya1993)	Severe scrotal syndrome***	--	2/15 (13%)	--	--	0	--

Table 06. Specific adverse events (Continued)

Study	Adverse events	Placebo	ALB*	IVER*	ALB + IVER	DEC*	ALB + DEC
	Scrotal syndrome - mild, moderate, or severe	--	11/15 (73%)	--	--	0	--
	Fever, right hypochondrial pain and repeated vomiting	--	0/15	--	--	1/13 (8%)	--

FOOTNOTES

*ALB: albendazole; IVER:

ivermectin;

DEC: diethylcarbamazine

**All systemic adverse reactions recorded by assigning score 0 (none), 1 (mild), 2 (moderate), or 3 (severe)

***Mild:

epididymis felt enlarged and tender, and spermatic cord was tender and nodular, scrotal sac swollen; moderate: swelling of scrotal sac, tender epididymis, swelling, nodularity or cord, and some systemic features, eg fever malaise; severe: whole scrotal sac swollen and palpation quite painful, features of acute inflammation, eg redness, warmth,

Table 06. Specific adverse events (Continued)

Study	Adverse events	Placebo	ALB*	IVER*	ALB + IVER	DEC*	ALB + DEC
	pain, swelling, and systemic features such as fever, chills, anorexia, nausea						

GRAPHS

Comparison 01. Albendazole versus placebo

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)			Relative Risk (Fixed) 95% CI	Subtotals only
02 New clinical disease			Relative Risk (Fixed) 95% CI	Totals not selected
03 Pre-existing clinical disease			Relative Risk (Fixed) 95% CI	Totals not selected
04 Adverse events			Relative Risk (Fixed) 95% CI	Totals not selected
05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)	2	195	Relative Risk (Fixed) 95% CI	0.97 [0.87, 1.09]

Comparison 02. Albendazole versus ivermectin

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)			Relative Risk (Fixed) 95% CI	Totals not selected
02 New clinical disease			Relative Risk (Fixed) 95% CI	Totals not selected
03 Pre-existing clinical disease			Relative Risk (Fixed) 95% CI	Totals not selected
04 Adverse events			Relative Risk (Fixed) 95% CI	Totals not selected
05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)	2	198	Relative Risk (Fixed) 95% CI	0.84 [0.72, 0.98]

Comparison 03. Albendazole plus ivermectin versus ivermectin

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)			Relative Risk (Fixed) 95% CI	Totals not selected
02 New clinical disease			Relative Risk (Fixed) 95% CI	Totals not selected
03 Pre-existing clinical disease			Relative Risk (Fixed) 95% CI	Totals not selected
04 Adverse events			Relative Risk (Fixed) 95% CI	Totals not selected

05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)	2	197	Relative Risk (Random) 95% CI	0.57 [0.13, 2.48]
--	---	-----	-------------------------------	-------------------

Comparison 04. Albendazole versus DEC

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Microfilaraemia	2	56	Relative Risk (Fixed) 95% CI	0.92 [0.65, 1.30]
02 Adverse events			Relative Risk (Fixed) 95% CI	Totals not selected
03 Adverse events: scrotal syndrome			Relative Risk (Fixed) 95% CI	Totals not selected

Comparison 05. Albendazole plus DEC versus DEC

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 Microfilaraemia			Relative Risk (Fixed) 95% CI	Subtotals only
02 Adverse events			Relative Risk (Fixed) 95% CI	Subtotals only

INDEX TERMS

Medical Subject Headings (MeSH)

Albendazole [therapeutic use]; Diethylcarbamazine [therapeutic use]; Elephantiasis, Filarial [*drug therapy]; Filaricides [*therapeutic use]; Ivermectin [therapeutic use]; Randomized Controlled Trials

MeSH check words

Humans

COVER SHEET

Title	Albendazole for lymphatic filariasis
Authors	International Filariasis Review Group (David Addiss, Julia Critchley, Henry Ejere, Paul Garner, Hellen Gelband, Carrol Gamble)
Contribution of author(s)	Julia Critchley assessed studies for inclusion, extracted data, and is responsible for preparing the review. Henry Ejere wrote the protocol, assessed studies for inclusion, and extracted data. Paul Garner edited the protocol and review, extracted data, and assessed study methodological quality. David Addiss and Hellen Gelband edited the protocol and review. Carrol Gamble edited the protocol and review, and provided statistical input.
Issue protocol first published	2002/3
Review first published	2004/1
Date of most recent amendment	26 May 2005
Date of most recent SUBSTANTIVE amendment	24 October 2003
What's New	DEVIATIONS FROM PROTOCOL (1) Reviewers: Julia Critchley was invited to join the review team. (2) Objectives: These have been reworded. (3) Methods: Subgroups dropped because no longer appropriate.

Date new studies sought but none found Information not supplied by author

Date new studies found but not yet included/excluded 05 April 2005

Date new studies found and included/excluded Information not supplied by author

Date authors' conclusions section amended Information not supplied by author

DOI 10.1002/14651858.CD003753.pub2

Cochrane Library number CD003753

Editorial group Cochrane Infectious Diseases Group

Editorial group code HM-INFECTN


GRAPHS AND OTHER TABLES

Comparison 05. 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)

Review: Albendazole for lymphatic filariasis

Comparison: 01 Albendazole versus placebo

Outcome: 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)




Comparison 05. 02 New clinical disease

Review: Albendazole for lymphatic filariasis

Comparison: 01 Albendazole versus placebo

Outcome: 02 New clinical disease




Comparison 05. 03 Pre-existing clinical disease

Review: Albendazole for lymphatic filariasis

Comparison: 01 Albendazole versus placebo

Outcome: 03 Pre-existing clinical disease




Comparison 05. 04 Adverse events

Review: Albendazole for lymphatic filariasis

Comparison: 01 Albendazole versus placebo

Outcome: 04 Adverse events




Comparison 05. 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)

Review: Albendazole for lymphatic filariasis

Comparison: 01 Albendazole versus placebo

Outcome: 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)




Comparison 05. 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)

Review: Albendazole for lymphatic filariasis

Comparison: 02 Albendazole versus ivermectin

Outcome: 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)




Comparison 05. 02 New clinical disease

Review: Albendazole for lymphatic filariasis

Comparison: 02 Albendazole versus ivermectin

Outcome: 02 New clinical disease




Comparison 05. 03 Pre-existing clinical disease

Review: Albendazole for lymphatic filariasis

Comparison: 02 Albendazole versus ivermectin

Outcome: 03 Pre-existing clinical disease




Comparison 05. 04 Adverse events

Review: Albendazole for lymphatic filariasis

Comparison: 02 Albendazole versus ivermectin

Outcome: 04 Adverse events




Comparison 05. 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)

Review: Albendazole for lymphatic filariasis

Comparison: 02 Albendazole versus ivermectin

Outcome: 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)




Comparison 05. 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)

Review: Albendazole for lymphatic filariasis

Comparison: 03 Albendazole plus ivermectin versus ivermectin

Outcome: 01 Microfilaraemia in all participants (both microfilariae positive or negative at baseline)




Comparison 05. 02 New clinical disease

Review: Albendazole for lymphatic filariasis

Comparison: 03 Albendazole plus ivermectin versus ivermectin

Outcome: 02 New clinical disease




Comparison 05. 03 Pre-existing clinical disease

Review: Albendazole for lymphatic filariasis

Comparison: 03 Albendazole plus ivermectin versus ivermectin

Outcome: 03 Pre-existing clinical disease




Comparison 05. 04 Adverse events

Review: Albendazole for lymphatic filariasis

Comparison: 03 Albendazole plus ivermectin versus ivermectin

Outcome: 04 Adverse events




Comparison 05. 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)

Review: Albendazole for lymphatic filariasis

Comparison: 03 Albendazole plus ivermectin versus ivermectin

Outcome: 05 Microfilaraemia in participants microfilariae positive at baseline (microfilariae negative excluded)




Comparison 05. 01 Microfilaraemia

Review: Albendazole for lymphatic filariasis

Comparison: 04 Albendazole versus DEC

Outcome: 01 Microfilaraemia




Comparison 05. 02 Adverse events

Review: Albendazole for lymphatic filariasis

Comparison: 04 Albendazole versus DEC

Outcome: 02 Adverse events




Comparison 05. 03 Adverse events: scrotal syndrome

Review: Albendazole for lymphatic filariasis

Comparison: 04 Albendazole versus DEC

Outcome: 03 Adverse events: scrotal syndrome




Comparison 05. 01 Microfilaraemia

Review: Albendazole for lymphatic filariasis

Comparison: 05 Albendazole plus DEC versus DEC

Outcome: 01 Microfilaraemia



Comparison 05. 02 Adverse events

Review: Albendazole for lymphatic filariasis

Comparison: 05 Albendazole plus DEC versus DEC

Outcome: 02 Adverse events

